Trial · NCT01966471
Results by group551
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 551
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Invasive Disease-Free Survival (IDFS) in the Node-Positive Subpopulation | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | 94.10 | 95% Confidence Interval 92.46 to 95.73 | Percent Probability | |
| Invasive Disease-Free Survival (IDFS) in the Node-Positive Subpopulation | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 92.75 | 95% Confidence Interval 90.95 to 94.54 | Percent Probability | |
| Invasive Disease-Free Survival (IDFS) in the Overall Population | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | 94.22 | 95% Confidence Interval 92.68 to 95.76 | Percent Probability | |
| Invasive Disease-Free Survival (IDFS) in the Overall Population | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 93.06 | 95% Confidence Interval 91.40 to 94.73 | Percent Probability | |
| IDFS Plus Second Primary Non-Breast Cancer | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | 93.43 | 95% Confidence Interval 91.79 to 95.06 | Percent Probability | |
| IDFS Plus Second Primary Non-Breast Cancer | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 92.26 | 95% Confidence Interval 90.51 to 94.02 | Percent Probability | |
| Disease-Free Survival (DFS) | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | 93.32 | 95% Confidence Interval 91.67 to 94.97 | Percent Probability | |
| Disease-Free Survival (DFS) | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 92.04 | 95% Confidence Interval 90.26 to 93.81 | Percent Probability | |
| Distant Recurrence-Free Interval (DRFI) | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | 95.23 | 95% Confidence Interval 93.82 to 96.64 | Percent Probability | |
| Distant Recurrence-Free Interval (DRFI) | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 94.91 | 95% Confidence Interval 93.46 to 96.36 | Percent Probability | |
| Overall Survival (OS) | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | 96.03 | 95% Confidence Interval 94.72 to 97.34 | Percent Probability | |
| Overall Survival (OS) | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 94.86 | 95% Confidence Interval 93.40 to 96.32 | Percent Probability | |
| Percentage of Participants With Adverse Events | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | 98.5 | Percentage of participants | ||
| Percentage of Participants With Adverse Events | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 99.1 | Percentage of participants | ||
| Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | Decrease from baseline <10 Ejection Fraction (EF) points | 506 | Participants | |
| Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | Decrease from baseline <10 Ejection Fraction (EF) points | 522 | Participants | |
| Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | Absolute value >= 50% and decrease from baseline >= 10 EF points | 254 | Participants | |
| Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | Absolute value >= 50% and decrease from baseline >= 10 EF points | 245 | Participants | |
| Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | Absolute value < 50% and decrease from baseline >= 10 EF points | 71 | Participants | |
| Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | Absolute value < 50% and decrease from baseline >= 10 EF points | 35 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01966471/results